OptiBiotix Health PLC Director Appointment (1750A)

TIDMOPTI

RNS Number : 1750A

OptiBiotix Health PLC

10 September 2018

OptiBiotix Health plc

("OptiBiotix")

Director Appointment

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, announces that, further to the previous announcement made on 6 August 2018 regarding the proposed appointment of Sean Christie as Non-Executive Director of the Company, the regulatory due diligence process has now been completed and the text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Michael Sean Christie (aged 60):

 
 Current Appointments         Appointments in the last 
                               5 years 
 ACCSYS Technologies Plc      Croda Enterprises Limited 
 Applied Graphene Materials   Croda Europe Limited 
  Plc 
 Turner & Townsend Limited    Croda International Plc 
                              Croda Investments Limited 
                              Croda Investments No 2 Limited 
                              Croda JDH Limited 
                              Croda Overseas Holdings 
                               Limited 
                              Croda Polymers International 
                               Limited 
                              Croda World Traders Limited 
                              Eminate Limited 
                              Produce Investments Limited 
 

For further information, please contact:

 
 OptiBiotix Health plc                                            www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                Contact via Walbrook 
                                                                               below 
 
 Cairn Financial Advisers LLP (NOMAD)                             Tel: [phone] 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
   finnCap (Broker)                                               Tel: [phone] 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                     Tel: [phone] or [e-mail] 
 Anna Dunphy                                                      Mob: [phone] 
 Lianne Cawthorne                                                 Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAUGURGBUPRGCM

(END) Dow Jones Newswires

September 10, 2018 02:00 ET (06:00 GMT)